Elevated Basic Fibroblast Growth Factor Levels: Plasma bFGF Levels

We examined the possibility that there may be a threshold level for urine bFGF. Using the 95th percentile in our control subjects as an upper limit of normal, we found that 21% of patients with PAH had elevations in urine bFGF. Twenty-six percent of patients with PPH, and 14% of patients with PAH-other (11% CHD and 19% CTD) had abnormally elevated urine bFGF levels (p = 0.008).
Median plasma levels of bFGF were significantly higher in patients with PAH than in control subjects (median, 1.9 pg/mL vs 0.5 pg/mL; p = 0.02). There was a difference in plasma bFGF levels based on etiology (PPH, 2.1 pg/mL; CHD, 1.7 pg/mL; CTD, 1.0 pg/mL; p = 0.3), but the only significant pairwise comparison was between PPH and control subjects (p = 0.05) [Fig 2, 3]. There was no significant difference between male and female patients.

We examined the possibility that there may be a threshold level for plasma bFGF. Using the 95th percentile in our control subjects as an upper limit of normal, we found that 51% of patients with PAH had elevations in plasma bFGF. Fifty-five percent of patients with PPH and 43% of patients with PAH-other had abnormally elevated plasma bFGF levels (p = 0.015). canadianfamilypharmacy

Urine and Plasma VEGF Levels
There was no significant difference in median levels of urine VEGF (95 pg/mL vs 84 pg/mL, p = 0.9) between patients and control subjects. Overall, 7% of patients with PAH had elevated urine VEGF values (6% of patients with PPH and 8% of patients with PAH-other). Median levels of plasma VEGF were qualitatively higher in patients with PPH (41.4 pg/mL) than in those with PAH (21.8 pg/mL) or control subjects (13.2 pg/mL, p = 0.06), Overall, 7.5% of patients with PAH had elevated plasma VEGF values. Elevations in circulating VEGF were largely confined to the PPH group (12% of patients with PPH and 2% of patients with PAH-other). Differences were not significant within the subgroup of male vs female patients.
Fig2
Figure 2. Plasma bFGF levels (median, IQR) by etiology of PAH. There is a significant difference in median plasma bFGF level between the groups (p = 0.05). The only significant pairwise comparison is between PPH and control subjects.
Fig3
Figure 3. Mean (± SEM) urine and plasma bFGF levels by diagnostic group. There is a similar distribution of bFGF levels by diagnostic group for both urine and plasma bFGF. Highest bFGF levels for both urine and plasma are seen in PPH.

This entry was posted in Hypertension and tagged angiogenesis, growth substances, pulmonary heart disease.